Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Ackerman MD, PhD

Michael J. Ackerman MD, PhD

Windland Smith Rice Cardiovascular Genomics Research Professor; Professor of Medicine, Pediatrics, and Pharmacology; Director of the Windland Smith Rice Genetic Heart Rhythm Clinic and Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota

Michael J. Ackerman is the Windland Smith Rice Cardiovascular Genomics Research Professor and Professor of Medicine, Pediatrics, and Pharmacology at the Mayo Clinic in Rochester, Minnesota.

Dr. Ackerman received his MD and PhD from the Mayo Clinic Alix School of Medicine and the Mayo Clinic Graduate School of Biomedical Sciences and residency and fellowship training in Pediatric and Pediatric Cardiology in the Mayo Clinic School of Graduate Medical Education.

Currently, he serves as director of Mayo Clinic’s Windland Smith Rice Genetic Heart Rhythm Clinic and the Windland Smith Rice Sudden Death Genomics Laboratory. He has published over 650 peer-reviewed articles. Dr. Ackerman has also served as the president of the Sudden Arrhythmia Death Syndromes (SADS) Foundation since 2006.

In 2015, he received Mayo Clinic’s Distinguished Clinician Award. In 2018, he received the Mayo Clinic Distinguished Pediatric Investigator Award and the Distinguished Scientist Award from the Heart Rhythm Society. In 2021, he was inducted into the prestigious Association of American Physicians and received the Mayo Clinic Distinguished Investigator Award.

Disclosures

Dr. Ackerman reports the following:

  • Consultant: Abbot, BioMarin Pharmaceuticals, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Illumina, Invitae, Medtronic, Tenaya Therapeutics, and UpToDate
  • IP/Royalties: AliveCor, Anumana, ARMGO Pharma, Pfizer, and Thryv Therapeutics.

Recent Contributions to PracticeUpdate:

  1. Type of Syncope Trigger and Risk of Subsequent Life-Threatening Events in Patients With Long QT Syndrome
  2. Arrhythmia Variants in a Multi-Center Cohort
  3. Effectiveness of ICDs to Reduce Mortality in Patients With Long QT Syndrome
  4. Interplay Among Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome
  5. The Molecular Autopsy From Down Under
  6. Sudden Cardiac Death Among Children and Young Adults
  7. Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in EMR
  8. MY APPROACH to Treatment of the Congenital Long QT Syndromes

Most Read This Week

Recently Updated